Stimcell Energetics Inc.
Stimcell Energetics is a biotech company focused on developing therapeutic and non-therapeutic products intended to enhance cellular function, promote general wellness and address health complications. Its main technology, eBalance®, uses subsensory microcurrent electrical therapy and is the basis for the eBalance® Pro System, designed for healthcare professionals in clinical settings, and the eBalance® Home System, designed for patient use at home. The systems deliver programmed treatments for wellness and pain management. Stimcell also works on an eBalance® Wellness consumer device with diagnostic features. The company has suspended research and development of eBalance® Technology and sales of its Home and Pro systems after its Health Canada licenses were cancelled. Its stated revenue sources include device sales and recurring fees for treatment packages. Stimcell is headquartered in Vancouver, British Columbia, Canada.
No SEC Form 4 filings for $STME in the last 30 days.
See all $STME insider activity →StimCell Energetics (OTCQB:STME) reported preliminary study results showing its eBalance technology improved mitochondrial function in rat neurons. Key metrics like basal and maximal respiration increased significantly. The study, with St. Boniface Hospital, is ongoing, and results are preliminary. STME focuses on cellular function enhancement.
Stimcell Energetics Inc. reported Q2 2026 results with revenue of $160.21K, a 40.1% decrease YoY, and a net loss of $169.52K, a 36.2% improvement. Diluted loss per share remained at $0.01. The company is redesigning its eBalance® Home device and conducting clinical studies. It aims to list on the Canadian Securities Exchange and is pursuing fundraising efforts.
Stimcell Energetics Inc. (STME) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions Vancouver, BC – September 8, 2026 - StimCell Energetics Inc. ( OTCQB: STME ) (“StimCell” or the “Company”), a biotech pioneer targeting cellular energy to enha
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning STME (Stimcell Energetics Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent STME coverage spans corporate actions, financial news and earnings.
Positive preclinical data may boost investor sentiment and support near‑term price appreciation.
The company posted a small loss narrowing and modest revenue, likely keeping the stock under pressure.
The advisory agreement may facilitate future capital raises, potentially supporting share price if financing is secured.
The advisory deal may facilitate future equity or debt financing, modestly improving liquidity prospects.
AlphAI scores every news story that mentions STME with an AI model for sentiment and relevance, and aggregates insider trades from Stimcell Energetics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
StimCell Energetics (OTCQB:STME) reported preliminary study results showing its eBalance technology improved mitochondrial function in rat neurons. Key metrics like basal and maximal respiration increased significantly. The study, with St. Boniface Hospital, is ongoing, and results are preliminary. STME focuses on cellular function enhancement.
Stimcell Energetics Inc. reported Q2 2026 results with revenue of $160.21K, a 40.1% decrease YoY, and a net loss of $169.52K, a 36.2% improvement. Diluted loss per share remained at $0.01. The company is redesigning its eBalance® Home device and conducting clinical studies. It aims to list on the Canadian Securities Exchange and is pursuing fundraising efforts.
Stimcell Energetics Inc. (STME) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. StimCell Energetics Engages Stonegate Capital Markets as Non-Exclusive Advisor for Strategic Capital Market Transactions Vancouver, BC – September 8, 2026 - StimCell Energetics Inc. ( OTCQB: STME ) (“StimCell” or the “Company”), a biotech pioneer targeting cellular energy to enha
StimCell Energetics (OTCQB:STME) has engaged Stonegate Capital Markets as a non-exclusive advisor to identify investors and strategic partners for potential transactions, including debt or equity offerings. The agreement aims to support the company's growth and advance its eBalance technology. Compensation will be a success-based fee upon closing any transaction.
